최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.28 no.4, 2018년, pp.333 - 341
박현진 (서울대학교 약학대학, 종합약학연구소) , 최보윤 (서울대학교 약학대학, 종합약학연구소) , 손민지 (서울대학교 약학대학, 종합약학연구소) , 한나영 (서울대학교 약학대학, 종합약학연구소) , 김인화 (서울대학교 약학대학, 종합약학연구소) , 오정미 (서울대학교 약학대학, 종합약학연구소)
Objective: Tumor necrosis factor-alpha (TNF-alpha) inhibitors are used as a treatment in various immune-mediated inflammatory diseases (IMIDs). Tuberculosis (TB) risk is reported in several meta-analyses in patients treated with TNF-alpha inhibitors. The purpose of this study is to collect, review, ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Bradley, JR. TNF-mediated inflammatory disease. The Journal of pathology : a journal of the Pathological Society of Great Britain and Ireland, vol.214, no.2, 149-160.
Firestein GS, and Corr M. Common mechanisms in immune-mediated inflammatory disease. J Rheumatol Suppl 2005;73:8-13.
Kuek, Annabel, Hazleman, Brian L, Östör, Andrew J K. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgraduate medical journal, vol.83, no.978, 251-260.
Blandizzi, C., Gionchetti, P., Armuzzi, A., Caporali, R., Chimenti, S., Cimaz, R., Cimino, L., Lapadula, G., Lionetti, P., Marchesoni, A., Marcellusi, A., Mennini, F.S., Salvarani, C., Girolomoni, G.. The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. International journal of immunopathology and pharmacology, vol.27, no.1, 1-10.
Burmester, G. R, Mariette, X., Montecucco, C., Monteagudo-Saez, I., Malaise, M., Tzioufas, A. G, Bijlsma, J. W J, Unnebrink, K., Kary, S., Kupper, H.. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Annals of the rheumatic diseases : the official journal, vol.66, no.6, 732-739.
Sampaio-Barros, P.D., van der Horst-Bruinsma, I.E.. Adverse effects of TNF inhibitors in SpA: Are they different from RA?. Best practice & research. Clinical rheumatology, vol.28, no.5, 747-763.
Askling, Johan, Fored, C. Michael, Brandt, Lena, Baecklund, Eva, Bertilsson, Lennart, Cöster, Lars, Geborek, Pierre, Jacobsson, Lennart T., Lindblad, Staffan, Lysholm, Jörgen, Rantapää-Dahlqvist, Solbritt, Saxne, Tore, Romanus, Victoria, Klareskog, Lars, Feltelius, Nils. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis and rheumatism, vol.52, no.7, 1986-1992.
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., Symmons, D. P. M.. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and rheumatism, vol.54, no.8, 2368-2376.
Ai, Jing-Wen, Zhang, Shu, Ruan, Qiao-Ling, Yu, Yi-Qi, Zhang, Bing-Yan, Liu, Qi-Hui, Zhang, Wen-Hong. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies. The Journal of rheumatology, vol.42, no.12, 2229-2237.
Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G.K., Peyrin-Biroulet, L., Danese, S.. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol.14, no.10, 1385-1397.e10.
Capogrosso Sansone, Alice, Mantarro, Stefania, Tuccori, Marco, Ruggiero, Elisa, Montagnani, Sabrina, Convertino, Irma, Marino, Alessandra, Fornai, Matteo, Antonioli, Luca, Corona, Tiberio, Garibaldi, Danila, Blandizzi, Corrado. Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. Drug safety : an international journal of medical toxicology and drug experience, vol.38, no.10, 869-888.
Ford, Alexander C, Peyrin-Biroulet, Laurent. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. The American journal of gastroenterology : official publication of the National Gastroenterological Association, vol.108, no.8, 1268-1276.
Liao, Hongxing, Zhong, Zhixiong, Liu, Zhanliang, Zou, Xuenong. Comparison of the risk of infections in different anti‐TNF agents: a meta‐analysis. International journal of rheumatic diseases, vol.20, no.2, 161-168.
Minozzi, Silvia, Bonovas, Stefanos, Lytras, Theodore, Pecoraro, Valentina, González-Lorenzo, Marien, Bastiampillai, Anan Judina, Gabrielli, Eugenia Maria, Lonati, Andrea Carlo, Moja, Lorenzo, Cinquini, Michela, Marino, Valentina, Matucci, Andrea, Milano, Giuseppe Maria, Tocci, Giuliano, Scarpa, Raffaele, Goletti, Delia, Cantini, Fabrizio. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert opinion on drug safety, vol.15, no.1, 11-34.
Ruiz Garcia, Vicente, Burls, Amanda, Cabello, Juan B, Vela Casasempere, Paloma, Bort-Marti, Sylvia, Bernal, José A. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. The Cochrane database of systematic reviews, vol.2017, no.9,
Singh, Jasvinder A, Noorbaloochi, Shahrzad, Singh, Gurkirpal. Golimumab for rheumatoid arthritis. The Cochrane database of systematic reviews, vol.2010, no.1,
Souto, Alejandro, Maneiro, José Ramón, Salgado, Eva, Carmona, Loreto, Gomez-Reino, Juan J.. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology, vol.53, no.10, 1872-1885.
Wang, Qiang, Wen, Zhenzhen, Cao, Qian. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Experimental and therapeutic medicine, vol.12, no.3, 1693-1704.
Xie, Xi, Chen, Jinwei, Peng, Youming, Gao, Jiesheng, Tian, Jing, Ling, Guanghui, Du, Jinfeng, Mao, Ni, Wu, Peijun, Li, Fen. [Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis].. 中南大學學報. Journal of Central South University. 醫學版, vol.38, no.7, 722-736.
Xu, Zhigao, Xu, Peipei, Fan, Wei, Yang, Gui, Wang, June, Cheng, Qingyuan, Yu, Mingxia. Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials. Experimental and therapeutic medicine, vol.14, no.4, 3491-3500.
Zhang, Zheng, Fan, Wei, Yang, Gui, Xu, Zhigao, Wang, June, Cheng, Qingyuan, Yu, Mingxia. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ open, vol.7, no.3, e012567-e012567.
Ke, W-M, Chen, L-S, Parng, I-M, Chen, W-W, On, A W F. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, vol.17, no.12, 1590-1595.
Wallis, Robert S. Reactivation of Latent Tuberculosis by TNF Blockade: The Role of Interferon γ. The journal of investigative dermatology. Symposium proceedings, vol.12, no.1, 16-21.
Chapter 1: introduction. Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane Collaboration 2011. Available from http://www.handbook.cochrane.org Accessed Oct 30 2018
Pollock, Michelle, Fernandes, Ricardo M., Becker, Lorne A., Featherstone, Robin, Hartling, Lisa. What guidance is available for researchers conducting overviews of reviews of healthcare interventions? A scoping review and qualitative metasummary. Systematic reviews, vol.5, no.1, 190-.
Deeks J, Higgins J, and Altman D, Chapter 9: Analysing data and undertaking meta-analyses, Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from http://www.cochrane-handbook.org Accessed Oct 30 2018
Fusar-Poli, Paolo, Radua, Joaquim. Ten simple rules for conducting umbrella reviews. Evidence-based mental health, vol.21, no.3, 95-100.
Cochrane handbook for systematic reviews of interventions (version 5.1.0). Chapter 22: overviews of reviews. The Cochrane Collaboration 2011. Available from http://www.handbook.cochrane.org Accessed Oct 30 2018
Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., Wallis, R. S., Sotgiu, G., Scholvinck, E. H., Goletti, D., Zellweger, J. P., Diel, R., Carmona, L., Bartalesi, F., Ravn, P., Bossink, A., Duarte, R., Erkens, C., Clark, J., Migliori, G. B., Lange, C.. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, vol.36, no.5, 1185-1206.
Wallis, R.S.. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. The Lancet. Infectious diseases, vol.8, no.10, 601-611.
Scallon, Bernie, Cai, Ann, Solowski, Nancy, Rosenberg, Amy, Song, Xiao-Yu, Shealy, David, Wagner, Carrie. Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists. The Journal of pharmacology and experimental therapeutics, vol.301, no.2, 418-426.
Scallon, Bernard J., Moore, Maria Arevalo, Trinh, Han, Knight, David M., Ghrayeb, John. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine, vol.7, no.3, 251-259.
Banner, D.W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.-J., Broger, C., Loetscher, H., Lesslauer, W.. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation. Cell, vol.73, no.3, 431-445.
Bonovas, Stefanos, Pantavou, Katerina, Evripidou, Despo, Bastiampillai, Anan Judina, Nikolopoulos, Georgios K., Peyrin-Biroulet, Laurent, Danese, Silvio. Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. Best practice & research. Clinical gastroenterology, vol.32, 43-47.
Adalimumab. Micromedex Solutions.Truven Health Analytics, Inc. Greenwood Village, CO Available from http://www.micromedexsolutions.com Accessed Oct 30 2018
Infliximab. Micromedex Solutions.Truven Health Analytics, Inc. Greenwood Village, CO Available from http://www.micromedexsolutions.com Accessed Oct 30 2018
Certolizumab pegol. Micromedex Solutions.Truven Health Analytics, Inc. Greenwood Village, CO Available from http://www.micromedexsolutions.com Accessed Oct 30 2018
Golimumab. Micromedex Solutions.Truven Health Analytics, Inc. Greenwood Village, CO Available from http://www.micromedexsolutions.com Accessed Oct 30 2018
Etanercept. Micromedex Solutions.Truven Health Analytics, Inc. Greenwood Village, CO Available from http://www.micromedexsolutions.com Accessed Oct 30 2018
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.